PRESS RELEASE: FILAMENT HEALTH ANNOUNCES CHANGE TO BOARD OF DIRECTORS

VANCOUVER, BC, Jan. 2, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that Maureen O’Connell has stepped down from her position as Director and Audit Committee Chair on the Company’s board of directors, effective December 31, 2023. O’Connell commented: “I have been part of […]

Go to Source

Powered by WPeMatico